Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 3/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099315 | 0.77 | ARG1 (0.43) | ARG1CACNA1BARG2DPP4DPP8 | |
| SCHEMBL7519612 | 0.77 | ARG1 (0.36) | ARG1VDRCACNA1BARG2SLC7A5 | |
| SCHEMBL7526170 | 0.77 | ARG1 (0.36) | ARG1VDRCACNA1BARG2SLC7A5 | |
| SCHEMBL4622520 | 0.75 | CAPN1 (0.51) | ARG1CAPN1 | |
| Hydrochloric Acid SCHEMBL8808672 | 0.74 | CAPN1 (0.50) | ARG1CAPN1 | |
| Hydrochloric Acid SCHEMBL8808683 | 0.74 | CAPN1 (0.50) | ARG1CAPN1 | |
| SCHEMBL6273912 | 0.74 | ARG1 (0.45) | ARG1CACNA1BARG2DPP4DPP8 | |
| SCHEMBL5096613 | 0.73 | CTSK (0.41) | ARG1CACNA1BARG2DPP4DPP8 | |
| SCHEMBL5096619 | 0.73 | CTSK (0.41) | ARG1CACNA1BARG2DPP4DPP8 | |
| SCHEMBL7451819 | 0.73 | TAS1R3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165222-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165222-A1 | Protease inhibitors | CTSK, CTSZ, CTSE | ARG1 3020/4885VDR 690/4885CACNA1B 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.